Gallagher Neil
SEC insider (Form 3/4/5 filer). CIK 0001972849. Director at Foghorn Therapeutics Inc. (FHTX) and 2 other issuers. 6 reported Form 4/5 transactions since Sep 2024; latest on Jun 24, 2026. Located in WATERTOWN, MA.
Companies Gallagher Neil has filed insider reports for
- Foghorn Therapeutics Inc. (FHTX): Director
- Syndax Pharmaceuticals Inc (SNDX): Officer, President, Head of R&D
- Zymeworks Inc. (ZYME): Director
Gallagher Neil
CIK: 0001972849
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 24, 2026FHTX
Foghorn Therapeutics Inc.
AwardDirectStock Options (Right to buy)
28K shares at avg. $4.08- - May 1, 2025FHTX
Foghorn Therapeutics Inc.
AwardDirectStock Options (Right to buy)
50K shares at avg. $4.16- - Feb 10, 2025SNDX
Syndax Pharmaceuticals Inc
SaleDirect4.6K shares at avg. $15.50$72K - Feb 5, 2025SNDX
Syndax Pharmaceuticals Inc
AwardDirect18.5K shares- - Feb 5, 2025SNDX
Syndax Pharmaceuticals Inc
AwardDirect23.4K shares- - Dec 10, 2024ZYME
Zymeworks Inc.
AwardDirectStock Option (Right to Buy)
31K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 24, 2026 |  FHTX Foghorn Therapeutics Inc. | Award Stock Options (Right to buy) | 28,000 | $4.08 | - | Direct |
| May 1, 2025 | FHTX Foghorn Therapeutics Inc. | Award Stock Options (Right to buy) | 50,000 | $4.16 | - | Direct |
| Feb 10, 2025 |  SNDX Syndax Pharmaceuticals Inc | Sale | 4,618 | $15.50 | $71,597 | Direct |
| Feb 5, 2025 | SNDX Syndax Pharmaceuticals Inc | Award | 18,500 | - | - | Direct |
| Feb 5, 2025 | SNDX Syndax Pharmaceuticals Inc | Award | 23,400 | - | - | Direct |
| Dec 10, 2024 |  ZYME Zymeworks Inc. | Award Stock Option (Right to Buy) | 31,000 | - | - | Direct |
1-6 of 6 transactions